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NanotechnologyBased on the fact that quercetin (QUE) and resveratrol (RES) induce a synergic inhibition of the adipogenesis
and increase apoptosis in adipocytes, and that sodium deoxycholate (SDC) has necrotic effects, the
nanoencapsulation of QUE and RES into SDC-elastic liposomes is proposed as a new approach for dissolving
the subcutaneous fat. The concentration of constituents and the effect of the drug incorporation into cyclo-
dextrin inclusion complexes on the stability of QUE/RES-loaded liposomes were studied. The best liposomal
formulation reduced the use of phosphatidylcholine and cholesterol in 17.7% and 68.4%, respectively. Lipo-
somes presented a mean diameter of 149 nm with a polydispersion index of 0.3. The zeta potential of lipo-
somes was slightly negative (−13.3 mV) due to the presence of SDC in the phospholipid bilayer.
Encapsulation efﬁciency of QUE and RES into liposomes was almost 97%. To summarize, QUE/RES-loaded
elastic liposomes are stable and suitable for subcutaneous injection, thereby providing a new strategy for re-
ducing subcutaneous fat.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
The natural compounds quercetin (QUE) and resveratrol (RES) are
both ﬂavonoids that have effects on the biochemical and metabolic
functions of adipocytes, such as the inhibition of adipogenesis and the
induction of apoptosis. QUE and RES in association caused a reduction
in cell viability of more than 70% in primary human adipocytes and
3T3-L1 murine adipocytes [1,2]. The treatment of 3T3-L1 adipocytes
with QUE attenuated adipogenesis and decreased the expression of
adipogenesis-related factors and enzymes by up-regulating the levels
of phosphorylated adenosine monophosphate-activated protein kinase
and its substrate. Finally, QUE induced apoptosis by modulation of
the ERK and JNK pathways, down-regulating the expression of anti-
apoptotic bcl-2 and activation of caspase-3 [3]. RES caused the inhibi-
tion of cell proliferation during early preadipocyte development; the
inhibition of differentiation and lipid accumulation during later
preadipocyte development; and the induction of lipolysis and apoptosis
of mature adipocytes. RES alsomediated the down-regulation of adipo-
cyte speciﬁc transcription factors and enzymes via genes that modulate
mitochondrial function [4]. Moreover, RES activated the expression of
Sirt1, reducing lipid accumulation by the repression of PPARγ in differ-
entiated adipocytes [2].+55 81 21268485.
es).
rights reserved.Despite the action of QUE and RES in reducing adipocyte viability,
there are few in vivo studies in this subject and the use of both these ﬂa-
vonoids for improving dissolution of subcutaneous fat is not described
in the literature. In addition, QUE and RES have low aqueous solubility
and low bioavailability [5]. In this way, liposomes offered advantages
in the attempt to overcome all these limitations. Liposomes are
self-assembled colloidal vesicles consisting of one or more concentric
phospholipid bilayers organized around an aqueous inner compart-
ment, and are used as nanocarriers for drugs, biomolecules and diag-
nostic agents [6,7]. Cevc and Blume [8] introduced the ﬁrst elastic
liposomes with high deformability (called Transfersomes®), which
are formed by the association of phosphatidylcholine (PC) with sodium
cholate or sodium deoxycholate (SDC), thus improving drug delivery.
The main difference between deformable and conventional liposomes
is the high and stress-dependent adaptability of such deformable vesi-
cles, which enables them to squeeze between the cells, despite their
large average vesicle size [9,10]. As reported, SDC is one of the compo-
nents of the subcutaneous “phosphatidylcholine injection” used to dis-
solve localised subcutaneous fat. SDC can also be used for treating
lipomas and lipodystrophy [11,12]. In this formulation, phosphatidyl-
choline acts as a buffer to delay and diminish the unopposed dramatic
effect of SDC. This leads to a massive fat necrosis by its detergent effect
and changes in the skin overlying the treatment region [11,13].
In this framework, the present studyproposes an innovative elastic li-
posomal formulation for the dissolution of subcutaneous fat. Two exper-
imental designs were developed to identify the constraints and to study
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SDC, the entrapment of QUE and RES in the phospholipid bilayer or their
encapsulation in the aqueous phase of liposomes as cyclodextrin inclu-
sion complexes. The stability of liposomes and the release kinetics of
QUE and RES were also investigated.
2. Materials and methods
2.1. Materials
Soya phosphatidylcholine (PC) (Epikuron 200) was obtained from
Lucas Meyer (Hamburg, Germany), 2-Hydroxypropyl-β-cyclodextrin
(HPβ-CD)were obtained from Fluka (Steinheim, Germany). Cholesterol
(CH), stearylamine (SA), phenolphthalein (PHP), poly-L-lysine, osmium
tetroxide, sodium deoxycholate (SDC), quercetin (QUE) and resveratrol
(RES) were obtained from Sigma (St. Louis, MO, USA). Acetonitrile,
chloroform, methanol and monobasic potassium phosphate were pur-
chased from Merck (Darmstadt, Germany). Analytical grade chemicals
without any further puriﬁcation and deionised water were used in all
the experiments.
2.2. Methods
2.2.1. Apparent solubility and dissolution rate of QUE and RES
Excess amounts of QUE and RES were added to water, 50 mM po-
tassium phosphate buffer solution (PP) at pH 7.4 or 50 mM phos-
phate buffered saline (PBS) at pH 7.4 following which they were
incubated at 37±1 °C and shaken until reaching equilibrium. The
content of QUE and RES was assessed by UV spectrophotometry
(Pharmacia Ultraspec 3000 Pro spectrophotometer) at 370 and
307 nm, respectively. The solubility was determined using the QUE
(0.31–20 μg/ml) and RES (0.02–20 μg/ml) standard curves, respec-
tively. The dissolution constant was calculated from the cumulative
amount of dissolved drug (μg) versus time (h) plots according to
USP [14]. Data were ﬁtted by linear regression analysis and the
slope of the linear equation corresponds to the dissolution rate.
2.2.2. Inclusion complexes of SDC, QUE and RES with HPβ-CD
Drug inclusion complexes with hydroxypropyl-β-cyclodextrin
(SDC:HPβ-CD; RES:HPβ-CD and QUE:HPβ-βCD) were prepared at a
1:1 molar ratio using the co-precipitation technique [15,16].
2.2.3. HPLC validation method for determining QUE and RES in elastic
liposomes
Samples of elastic QUE and RES-loaded liposomes were diluted in
methanol and injected into the HPLC system. Two different methods
for determiningQUE and RESwere validated. The chromatographic sys-
tem (FPLC ÄKTA puriﬁer) operated by the software UNICORN 4.1
(Amersham Biosciences) consisted of a quaternary pump (model
P-900), an auto sampler and a UV-900 detector (Amersham Biosci-
ences). The chromatographic run was performed using a reverse
phase C18 column (125 Å, 3.9×300 mn i.d. particle 5 μm, Bondapack®)
with 50 μl of the sample injection volume at 25 °C. HPLC analysis of QUE
(Method 1) was carried out using a mobile phase consisting of acetoni-
trile and methanol (4:6 v/v) at a ﬂow rate of 1.2 ml/min and detection
at 370 nm, while the assay of RES (Method 2) was performed using a
mobile phase consisting of acetonitrile and methanol (6:4 v/v) at a
ﬂow rate of 0.3 ml/min and detection at 307 nm.
The method for quantifying QUE and RES in elastic liposomes was
validated following the procedures presented by the European Medi-
cines Agency (EMEA, CPMP/ICH, 381, 95). Absorbance vs. concentra-
tions curves were plotted using standard solutions of QUE or RES at
concentrations ranging from 2 to 80 μg/ml and 1 to 50 μg/ml, respec-
tively. Assays were performed in triplicate. The linearity of the stan-
dard curves was validated for each drug by the least square methodand one-way analysis of variance (ANOVA), by assuming pb0.05.
The limits of detection and quantiﬁcation were also determined.
2.2.4. Preparation of elastic QUE/RES-loaded liposomes
SDC elastic liposomes containing QUE and RES entrapped in their
phospholipid bilayer or SDC:HPβ-CD, RES:HPβ-CD or QUE:HPβ-CD in-
clusion complexes encapsulated in their aqueous inner cavity were pre-
pared using the thin lipid ﬁlm method [17,18]. Brieﬂy, a thin lipid ﬁlm,
named as organic phase (OP), consisting of PC and CH with or without
SA was produced from a mixture of CHCl3:MeOH (3:1 v/v) under mag-
netic stirring. The solvents were removed under pressure at 37±1 °C,
80 rpm for 60 min. This ﬁlmwas then hydrated with 10 ml of an aque-
ous phase (AP) containing 50 mM potassium phosphate buffer (PP) at
pH 7.4 or 50 mM phosphate buffered saline (PBS) at pH 7.4, resulting
in the formation of multilamellar liposomes. This liposomal suspension
was then sonicated (Vibra Cell, BRANSON, USA) at 200 W and 40 Hz for
300 s under low temperature (4 °C) to form small unilamellar lipo-
somes. SDC, QUE or RES were placed in the organic phase for the lipid
ﬁlm formation; and SDC:HPβ-CD, RES:HPβ-CD and QUE:HPβ-βCD
were placed in the aqueous phase during the lipid ﬁlm redispersion.
Lyophilised liposomes were obtained using threalose (10%) as
cryoprotectant. Samples were frozen at −80 °C and lyophilised
(EZ-DRY, FTSS System, New York, USA) at 200 bars for 48 h.
2.2.5. Experimental designs
At ﬁrst, a two-level 25−1 fractional experimental design was carried
out to optimize the formulation of liposomes. Factors of formulation
that mainly inﬂuenced the physicochemical characteristics of liposomes
(such as constituent concentrations (PC and CH) and drug inclusion com-
plexes with HPβ-CD) were evaluated at two levels and central point. The
factors were deﬁned as follows: Factor A=PC (69.95, 82.32 and
94.69 mM); Factor B=CH (18.74, 23.52 and 28.30 mM); Factor C=
SDC in the organic phase (OP=1.45–0.725 mM) or in the aqueous
phase (AP=1.45–0.725 mM); Factor D=QUE (OP=0.66–0.33 mM
and AP=0.66–0.33 mM); Factor E=RES (OP=0.88–0.44 mM and
AP=0.88–0.44 mM). The mean size, polydispersity index (PDI), zeta po-
tential (ζmV) and drug encapsulation efﬁciency (EE%) of liposomeswere
used as the response variables of the design study. Next, a two-level 23 -
full experimental design was employed for studying the drug concentra-
tion effects and the co-encapsulation of QUE and RES (1:1molar ratio) on
the liposomal physicochemical parameters evaluated at two levels and
central point as mentioned above. The factors were deﬁned as follows:
Factor A=CH (13.96, 18.74 and 23.52 mM); Factor B=SDC (1.45,
3.625 and 5.80 mM); Factor C=QUE and RES (1.54, 3.08 and 4.62 mM).
2.2.6. Physicochemical characterisation of elastic QUE/RES-loaded
liposomes
Drug encapsulation efﬁciency (EE%) was determined through the
ultraﬁltration/ultracentrifugation technique using Ultrafree® units
(Millipore, USA). After centrifugation of the samples (Ultracentrifuge
KT-20000, Kubota, Japan) at 8776g for 1 h at 4 °C, the contents of QUE
and RES in the supernatant were measured by a validated HPLCmeth-
od as described above. The EE% was determined as follow:
EE%Drug ¼
measuredDrug
h i
 unloadedDrug
h i
measuredDrug
h i ð1Þ
The total EE% was deﬁned in terms of the partial contents of QUE
and RES co-encapsulated in liposomes:
EE% ¼ 1
2
EE%QUE þ EE%RES
  ð2Þ
The particle size and polydispersity index (PDI) of elastic liposomes
were determined by standard photon correlation spectroscopy
Table 1
The apparent solubility and dissolution rate of QUE and RES at 37 °C.
Drug/solvent Solubility (μg/ml) Dissolution rate×102 (μg h−1)
QUE
Water 0.3 0.09
PP 3.2 2.00
PBS 2.2 1.00
RES
Water 21.0 8.00
PP 20.0 7.00
PBS 21.0 9.00
PP=50 mM phosphate potassium buffer (pH=7.4); PBS=50 mM phosphate buffer
saline (pH=7.4).
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angle of 90°. The zeta potential (ζ mV) of liposomes was measured at
25 °C using the electrophoresis technique (Zetatrac NC-148, Microtrac,
USA). The measurements were carried out for dispersed and
lyophylised forms of liposomes.
2.2.7. Scanning electron microscopy of elastic QUE/RES-loaded liposomes
Samples for scanning electron microscopy (SEM) evaluation were
obtained by dispersing a drop (20 μl) of the liposomal formulation
onto a coverslip containing poly-L-lysine solution (0.01% w/v), dried
at room temperature (25 °C) and ﬁxed with 2% osmium tetroxide
vapour for 1 h at 4 °C. The coverslip was then ﬁxed on an SEM-
stub using conductive double-sided tape, coated with a thin layer
(100 nm) of gold/palladium in a vacuum sputtering, and examined
(JSM-5600 microscope, Jeol, Japan) at 5 and 10 kV.
2.2.8. Stability of liposomal formulations
The stability of elastic QUE/RES-loaded liposomes was evaluated
using both the standard accelerated and the long-term stability testing.
Samples of conventional (QUE-Lipo and RES-Lipo) and SDC elastic QUE/
RES-loaded liposomes were submitted to centrifugation (3510g for
1 hour at 4 °C) and horizontal mechanical stirring (100 strokes/min
for 48 h at 37 °C). For long-term stability testing, samples of liposomes
in the dispersed forms were stored at 4 °C for 45 days. The mean size,
polydispersity index (PDI) and pH of formulations were analysed in
the assays.
2.2.9. In vitro release kinetics of QUE and RES from elastic liposomes
The release kinetics of QUE and RES from elastic liposomes was
performed using the dialysis sac technique (cellulose membrane,
cut-off=12,400 MW, Sartorius, Germany). For this purpose, sink
conditions were established according to apparent solubility studies
(item 2.2.1). An aliquot of 0.4 ml elastic liposomes was transferred
to the dialysis sac, which was sealed and immersed in dark ﬂasks
containing 250 ml of 100 mM potassium phosphate buffer solution
(pH 7.4). The release system was maintained under magnetic stirring
(100 rpm) at 37±1 °C. At a predetermined sampling time, 1 ml ali-
quot of medium was drawn and replaced with the same volume of
fresh release medium. QUE and RES content were measured by
HPLC as described above. Results are expressed as the percentage of
released drug as a function of time and values represent the
mean±standard deviation (SD) of three assay replicates.
2.2.10. Statistical analysis
The statistical analyses of data were carried out using the Statistica
6.0® software (StatSoft Inc., Tulsa, OK, USA). Differences were consid-
ered signiﬁcant at pb0.05.
3. Results
3.1. Apparent solubility and dissolution rate of QUE and RES
The results of the apparent solubility of QUE and RES inwater, 50 mM
PP buffer solution and 50 mMPBS at pH7.4 are shown in Table 1. The sol-
ubility of QUE increased tenfold in PP buffer solution at 7.4 pH (3.2 μg/ml)
with respect to its solubility in water (0.3 μg/ml). This result is explained
by the slight ionization of QUE that occurred at pH 7.4 (pKa=6.74) [19].
These results corroborate those previously reported by Priprem et al. [20],
where a QUE solubility of 0.7 μg/ml inwater and 4.3 μg/ml in 7.4 pH buff-
er solutions at 37 °C, respectively, was determined. On the other hand, no
change in the solubility of RES was found in pH 7.4 buffer solutions be-
cause no ionization of the RES molecule that occurred at this pH (pKa=
9.3) [21]. These results were not unexpected bearing in mind the pKa
values of these ﬂavonoids. Further, as the QUEmolecule has the potential
to ionize phenolic hydroxyl groups, a pH-dependent solubility is to be
expected. As previously described for a QUE dissolution study [22] atlower a pH, the free H+ ion tends to keep QUE in its molecular state
and its ionization is avoided. On the other hand, the concentration of
H+ ion decreases gradually with an increase in pH. Therefore, at high
pH QUE behaves as a weak acid, which means that QUE is being ionized,
leading to an increase in its solubility.
3.2. Inclusion complexes of SDC, QUE and RES with HPβ-CD
The Kc1:1 of SDC:HPβ-CD was determined according to Cadena
et al. [15] with value of 2.12×104 M−1. The Kc1:1 of QUE:HPβ-CD
and RES:HPβ-CD inclusion complexes were previously determined
by Jullian et al. [23] and Lu et al. [24] with values of 1.42×103 M−1
and 1.82×103 M−1, respectively.
3.3. HPLC validation method for determining QUE and RES in elastic
liposomes
Two independent HPLC methods were validated to quantify QUE
and RES in liposomes without drug extraction. The detection was
carried out at different wavelengths, 370 nm for QUE and 307 nm
for RES. The retention time of QUE was 3.56 min (Method 1) and
11.13 min for RES detection (Method 2). The standard curves for
the linearity assays were plotted with ﬁve concentrations allowing
the derivation of the following regression linear equations: A=3.86
(± 0.17)×[QUEμg/ml]−13.31 (± 7.93) and A=23.31 (± 0.33)×
[RESμg/ml] −24.29 (± 9.6). The standard curves were validated by
the least squares method showing correlation coefﬁcients higher as
0.9975 and the one-way analysis of variance (ANOVA) showing
F and p values of 57,133.04 and 0.0002 for QUE and 4,884.57 and
less than 6×10−6 for RES, respectively. The limits of detection
were 0.78 μg/ml for QUE and 0.13 μg/ml for RES, respectively. The
corresponding limits of quantiﬁcation were 2.59 and 0.43 μg/ml,
respectively.
3.4. Properties of elastic QUE/RES-loaded liposomes
After the formulation, the macroscopic appearance of the liposomal
dispersions was observed. Liposomal formulations exhibited a milky
appearance with a typically bluish reﬂection characteristic of
nanometric dispersed vesicles [18]. Table 2 shows the effect of the PP
or PBS buffers on the properties of liposomes. No signiﬁcant differences
in mean size between PP-liposomes with or without SA and
PBS-liposomes with SA were observed using the Tukey test (pb0.05).
However, PBS-liposome without SA showed the largest mean size. A
slight increase in the mean diameter of the liposomes without SA
occurred, probably due to an increase of the vesicle aggregation, given
the low zeta potential of liposomes. Suitable PDI values were obtained
in all formulations. Based on these results, PP-liposomes were thus
chosen for nanoencapsulation of drugs.
The physicochemical characteristics of elastic QUE/RES-loaded
liposomes are shown in Table 2. Elastic liposomes with SA showed
smaller sizes than those without SA. With reference to the PDI value,
no signiﬁcant differences were observed. QUE-loaded liposomes
Table 2
Pre-formulation study of SDC elastic liposomes containing QUE, RES or inclusion
complexes using different buffer solutions.
Liposomal
formulations*
Mean size
(nm)
PDI ζ
(mv)
EE
(%)
PC-CH-SA-PP 117.1±10.1a 0.291ab 21.87±1.55 ND
PC-CH-SA-PBS 130.6±10.3a 0.346b 32.42±0.74 ND
PC-CH-PP 133.3±11.1a 0.327ab −5.17±0.96 ND
PC-CH-PBS 166.7±20.6b 0.280a 0.47±0.01 ND
PC-CH-SA-SDC 110.8±13.4a 0.324a 21.68±2.72 ND
PC-CH-SDC 134.7±3.6b 0.301a −13.3±3.5 ND
PC-CH-SA-SDC:HPβCD 106.5±10.8a 0.320a 20.99±2.64 ND
PC-CH-SDC:HPβCD 123.6±8.5ab 0.314a −8.94±0.24 ND
PC-CH-SA-QUE 110.1±9.3a 0.347a 25.93±1.87 86.0±5.20a
PC-CH-QUE 124.9±2.1b 0.298a −3.72±1.37 97.3±1.30b
PC-CH-SA-QUE:HPβCD 146.1±5.6c 0.298a 22.86±1.67 93.9±1.76b
PC-CH-QUE:HPβCD 126.2±1.4b 0.272a −10.01±2.76 95.5±0.58b
PC-CH-SA-RES 118.8±9.5a 0.321a 22.91±1.46 96.4±2.64a
PC-CH-RES 142.5±5.1b 0.327a −0.47±0 98.3±0.86a
PC-CH-SA-RES:HPβCD 120.7±1.7a 0.272a 21.02±1.40 93.8±0.86a
PC-CH-RES:HPβCD 115.0±14.3a 0.337a −6.95±1.96 95.5±1.92a
*Molar ratio (mol/mol%): PC:CH (3.5:1), PC:CH:SA (7:2:1); [SDC=1.45]; [QUE=0.66];
[RES=0.88]; a-cMean values from three replicates. Average with different letters dif-
fers statistically by Tukey test (pb0.05); ND=not determined.
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no signiﬁcant differences were found in the PDI. QUE-loaded lipo-
somes with SA presented the lowest average diameter. In addition, It
was also observed that the SA inﬂuenced the UV absorptivity of QUE
(data not shown), resulting in a reduction of more than 10% in EE%.
Among the formulations produced with QUE, liposomes without SA
were chosen for further experiments because they showed a higher
EE%, as well as maintaining drug stability during the manufacturing
process. Furthermore, the mean size of liposomes was compatible
with the subcutaneous injection (> 100 nm), allowing them to re-
main at the site of injection [25]. In relation to the mean size, EE%
and PDI, RES-loaded liposomes showed no statistical signiﬁcant differ-
ences (pb0.05). RES-loaded liposomes without SA were thus chosen,
due to their higher EE% and also the co-encapsulation of QUE without
being affected by SA.Table 3
Two-level 25−1 fractional experimental design of elastic liposomes containing QUE and RE
Runs PC
(mM)
CH
(mM)
SDC
(mM)
QUE*
(mM)
RES*
(mM)
1 69.95 18.74 OP — 1.45 OP — 0.66 AP —
2 94.69 18.74 OP — 1.45 OP — 0.66 OP —
3 69.95 28.30 OP — 1.45 OP — 0.66 OP —
4 94.69 28.30 OP — 1.45 OP — 0.66 AP —
5 69.95 18.74 AP — 1.45 OP — 0.66 OP —
6 94.69 18.74 AP — 1.45 OP — 0.66 AP —
7 69.95 28.30 AP — 1.45 OP — 0.66 AP —
8 94.69 28.30 AP — 1.45 OP — 0.66 OP —
9 69.95 18.74 OP — 1.45 AP — 0.66 OP —
10 94.69 18.74 OP — 1.45 AP — 0.66 AP —
11 69.95 28.30 OP — 1.45 AP — 0.66 AP —
12 94.69 28.30 OP — 1.45 AP — 0.66 OP —
13 69.95 18.74 AP — 1.45 AP — 0.66 AP —
14 94.69 18.74 AP — 1.45 AP — 0.66 OP —
15 69.95 28.30 AP — 1.45 AP — 0.66 OP —
16 94.69 28.30 AP — 1.45 AP — 0.66 AP —
17 82.32 23.52 OP — 0.725
AP — 0.725
OP — 0.33
AP — 0.33
OP —
AP —
18 82.32 23.52 OP — 0.725
AP — 0.725
OP — 0.33
AP — 0.33
OP —
AP —
19 82.32 23.52 OP — 0.725
AP — 0.725
OP — 0.33
AP — 0.33
OP —
AP —
*Co-encapsulation of QUE and RES in the phospholipid bilayer or aqueous phase.3.5. Experimental designs
The nineteen experimental runs of the two-level 25−1 fractional
design and their responses are shown in Table 3. The experiments
were randomly evaluated in order to nullify the effect of inappropriate
nuisance variables. The preliminary runs (Table 2) were conducted
initially to establish the feasible range of each formulation parameter.
All liposomes had amean size compatiblewith subcutaneous injection
(> 100 nm), where the formulations preparedwith the lower concen-
tration of PC (69.65 mM) and SDC placed in the organic phase showed
the lowest PDI values (Table 3). In addition, the high values of zeta
potential were observedwhen SDC and RESwere placed in the organic
phase and the smallest PC concentration (69.65 mM) was used.
Finally, the greatest EE% was observed when SDC and RES were used
in the organic phase (pb0.05). The mean values of pH and absolute
viscosity values of all liposomal formulations were 7.64±0.07 and
0.372±0.001 mPa.s, respectively.
Fig. 1 shows the scatter plots indicating the best liposomal formu-
lations (runs 9 and 3), which have in common the lowest PC concen-
tration (69.65 mM), and SDC and RES placed in the organic phase.
QUE high encapsulation efﬁciency was found regardless of its location
in the organic or aqueous phase, allowing the choice of the organic
phase in order to design a simple and less expensive liposomal
formulation.
Based on these ﬁndings, a new experimental design was proposed,
taking into account the variables CH concentration and QUE and RES
co-encapsulation in the presence of SDC. The SDC concentration was
also studied as it can lead to an improvement in the zeta potential
of liposomes. The experimental runs of the two-level 23 full experi-
mental design and their responses are summarized in Table 4. The
concentration of CH was not statistically signiﬁcant for all physico-
chemical characteristics and was used in a minor concentration
(13.96 mM) for further experiments. These results are shown in
Fig. 2. The formulation prepared with CH, SDC, QUE and RES at
13.96, 5.8 and 4.62 mM (run 7) had the best parameters: high EE%
(97.5±0.06%), satisfactory values of mean size (149.4±2.47 nm)
and PDI (0.295±0.011). These elastic liposomes were morphologi-
cally analysed by SEM, exhibiting vesicles well dispersed without
aggregation (Fig. 3A) and spherical-shaped particles (Fig. 3B). InS or inclusion complexes.
Size
(nm)
PDI ζ
(mV)
EE
(%)
0.88 128.3±1.78 0.257 −7.73±0.68 92.26±0.52
0.88 139.5±6.04 0.305 −8.29±0.30 93.82±0.18
0.88 133.6±3.24 0.285 −13.34±1.36 93.92±0.14
0.88 122.5±4.82 0.284 −5.68±0.92 94.66±0.08
0.88 131.5±3.95 0.333 −5.72±0.50 93.34±0.25
0.88 164.5±3.52 0.342 −3.38±1.20 92.56±0.21
0.88 129.1±1.89 0.274 −7.35±1.23 89.62±0.75
0.88 133.3±2.48 0.262 −7.38±1.15 91.18±0.21
0.88 129.7±2.48 0.251 −16.69±0.85 90.84±0.70
0.88 129.4±2.71 0.264 −8.44±1.29 88.17±0.15
0.88 139.5±3.42 0.268 −8.54±0.20 85.37±0.41
0.88 135.9±2.03 0.272 −6.64±0.69 95.59±0.06
0.88 133.3±1.78 0.248 −6.28±1.59 87.30±0.82
0.88 138.2±1.89 0.485 −4.51±0.90 90.45±0.25
0.88 145.7±0.59 0.293 −6.03±0.23 87.29±1.15
0.88 123.6±3.79 0.374 −11.28±0.99 77.41±0.39
0.44
0.44
130.0±6.33 0.283 −9.98±0.93 89.41±0.11
0.44
0.44
133.3±5.05 0.284 −7.47±0.80 93.58±0.56
0.44
0.44
130.1±2.26 0.272 −10.28±0.98 92.85±0.19
Fig. 2. Scatter plot of the formulations produced using a 23 full experimental design
and effects of response variables zeta potential, polydispersity index, quercetin and
resveratrol concentrations (formulation number indicated above).
Fig. 1. Scatter plot of the formulations produced using a 25−1 fractional experimental
design and effects of response variables zeta potential, encapsulation efﬁciency and
polydispersity index (formulation number indicated above).
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as the lamellar structure of liposomes. But this phenomenon is due to
the ﬁxation with osmium tetroxide vapour [26]. The best formulation
had the mean size and PDI measured before and after its use through
1 ml insulin syringes. The results were not statically signiﬁcant by
Tukey test (pb0.05). The diameter of needle did not affect the liposo-
mal characteristics.3.6. Stability of liposomal formulations
Samples of conventional QUE-liposomes and RES-liposomes, and
SDC elastic QUE/RES-loaded liposomes were submitted to accelerated
stability testing (Table 5). No statistically signiﬁcant differences were
found (pb0.05) in the mean size and PDI for both conventional and
elastic liposomes assayed before and after centrifugation and hori-
zontal mechanical stirring. Moreover, the samples had the same mac-
roscopic appearance before and after standard accelerated stability
tests.
Liposomes were also submitted to long-term stability testing with
measurement of mean size and polydispersity index (Fig. 4). The SDC
elastic liposome had the lowest variation in the mean size (t0=
134.7±2.8 nm, t45=135.6±7.8 nm) and PDI (t0=0.300, t45=0.308)
when compared with QUE-Lipo (t0=146.6±1.4 nm, t45=150.4±
3.2 nm and t0=0.327, t45=0.347) and RES-Lipo (t0=140.9±2.2 nm,
t45=144.8±1.0 nm; t0=0.319, t45=0.328) after storage at 4 °C for
45 days. The inﬂuence of SDC on the stability of elastic compared toTable 4
Two-level 23 full experimental design and physicochemical properties of elastic QUE/RES-l
Runs CH
(mM)
SDC
(mM)
QUE+RES*
(1:1, mM)
Size
(nm)
1 13.96 1.45 1.54 153.11±
2 23.52 1.45 1.54 143.48±
3 13.96 5.80 1.54 124.93±
4 23.52 5.80 1.54 123.40±
5 13.96 1.45 4.62 142.00±
6 23.52 1.45 4.62 146.62±
7 13.96 5.80 4.62 149.43±
8 23.52 5.80 4.62 125.50±
9 18.74 3.625 3.08 141.07±
10 18.74 3.625 3.08 129.33±
11 18.74 3.625 3.08 120.99±
*Co-encapsulation of QUE and RES in the phospholipid bilayer.conventional liposomes was observed in Fig. 5. According to Gillet
et al. [9], the addition of SDC may reﬂect a deformation increase in
elastic liposomes, which can reduce stability, but this fact was not ob-
served in the present study.
Furthermore, the lowest pH variation of SDC elastic liposomes
(t0=7.42, t45=7.49) was found in comparison with RES-Lipo (t0=
7.46, t45=7.39) and QUE-Lipo (t0=7.58 and t45=7.17). A decrease
in the pH might indicate lipid degradation with fatty acids formation
[27], but this was not observed in the SDC elastic liposomes,
suggesting thus lower lipid peroxidation occurred. Further, the use
of 100 mM phosphate buffer seems to be suitable to prepare these li-
posomal formulations.
The elastic liposome had mean size of 179.04±2.90 nm, PDI of
0.290 and EE% of 95.45±0.12% before lyophilisation. The lyophilised
formulation was hydrated with water to the original volume and
the mean size of vesicles was measured (197.07±7.25 nm, PDI of
0.300). EE% was assayed as 95.26±0.15% and pH was 7.49. As
expected, it was observed a slight increase in the vesicle mean size
after hydration of the lyophilised liposomal formulation. In addition,
no statically signiﬁcant differences in PDI and EE% values (pb0.05)
were found after hydration of lyophilised liposomes.3.7. In vitro release kinetics of QUE and RES from elastic liposomes
As shown in Fig. 5, the in vitro release proﬁles of elastic QUE- and
RES-loaded liposomes were compared. QUE was released fromoaded liposomes.
PDI ζ
(mV)
EE
(%)
9.86 0.401±0.079 −7.29±0.97 98.53±0.27
4.87 0.278±0.027 −5.27±0.52 98.42±0.12
8.41 0.443±0.093 −12.23±0.84 97.55±0.07
3.85 0.354±0.038 −12.00±0.31 98.60±0.06
7.95 0.433±0.089 −7.07±0.37 99.50±0.04
9.82 0.486±0.083 −7.75±0.44 97.89±0.02
2.47 0.295±0.011 −13.48±0.25 97.49±0.06
2.57 0.300±0.011 −11.77±0.93 99.02±0.05
1.44 0.299±0.014 −12.09±0.53 98.73±0.04
6.14 0.351±0.051 −10.52±1.34 99.34±0.00
2.54 0.287±0.016 −9.98±0.82 98.42±0.09
Fig. 3. SEM micrographs of elastic QUE/RES-loaded liposomes.
Fig. 4. Long-term stability testing of conventional QUE-liposomes and RES-liposomes,
and SDC elastic QUE/RES-loaded liposomes after hydration of the lyophilised formula-
tion with storage at 4 °C.
Fig. 5. In vitro kinetic proﬁle of QUE/RES-loaded liposomes in 7.4 pH phosphate buffer
solution at 37 °C.
314 P.G. Cadena et al. / Biochimica et Biophysica Acta 1828 (2013) 309–316liposomes (56.3%) at 1 h, which corresponds to the burst effect. Next,
a controlled release was veriﬁed from 56.3% to 98.3% at 57 h. For RES,
the burst effect corresponded to 53.3% at 1 h, followed by a controlled
release from 53.3% to 96.4%, reaching the maximum release at 54.5 h.
The in vitro kinetic behaviour of QUE/RES-loaded liposomes seems to
be suitable bearing in mind that an initial burst effect is required to
quickly achieve levels as high as 100 μM of QUE and RES, which are
essential for the enhanced inhibition of adipogenesis and induction
of apoptosis [2].Table 5
Accelerated stability testing of liposomal formulations.
Formulation Mean size (nm)
Before
Centrifugation (3510g for 1 h at 4 °C)
SDC elastic QUE/RES-liposomes 135.9±10.1a
QUE-liposomes 141.5±4.8a
RES-liposomes 145.5±3.8a
Horizontal mechanical stirring (100 strokes/min for 48 h at 37 °C)
SDC elastic QUE/RES-liposomes 141.9±2.7a
QUE-liposomes 141.5±4.8a
RES-liposomes 145.5±3.8a
Mean data and standard deviation. Different letters differs statistically by Tukey test (pb0.04. Discussion
Treatments to dissolve subcutaneous fat based on the detergent
action of SDC in lipid structures with high concentrations of phospho-
lipid have been developed and commercialized, despite presenting
several adverse effects [12]. As a result, there has been a renewedPDI
After Before After
121.1±4.5a 0.325±0.02a 0.322±0.03a
131.9±5.6a 0.336±0.03a 0.318±0.03a
140.1±13.1a 0.328±0.02a 0.387±0.08a
141.2±8.2a 0.325±0.02a 0.331±0.02a
141.7±3.9a 0.336±0.03a 0.327±0.05a
149.8±5.8a 0.328±0.02a 0.358±0.06a
5).
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treatment with SDC. Keeping this in mind, this study focused on the
development and characterization of an innovative product based
on elastic SDC liposomes containing QUE and RES co-encapsulated
for subcutaneous administration.
It is well known that the stability of liposomes is dependent on
both formulation and manufacturing method parameters. In the
present study, the pre-formulation of liposomes varying the concen-
tration of constituents and the phase of incorporation was carried
out. The encapsulation of QUE or RES into liposomes altered the
mean size, PDI and surface charge in relation to unloaded liposomes
(Table 1). The presence of stearylamine, adds positive charged char-
acter to phospholipid bilayers of liposomes, caused a decrease of
about 10% in the encapsulation efﬁciency of quercetin (pb0.05).
However, high encapsulation efﬁciencies of QUE in liposomes pre-
pared with SA (PC:CH:SA, 7:2:1) or without SA (PC:CH, 7:2) were
attained (86±5.2% and 97.3±1.3%, respectively). Indeed, it has
been shown that QUE exhibits a high afﬁnity for liposomes as a result
of its planar conﬁguration, which can be easily intercalated into the
organized bilayer structure of the phospholipid molecules forming
the liposomes [28]. As previously reported, QUE-loaded liposomes
prepared with a mixture of egg phosphatidylcholine and cholesterol
at a 1:1 molar ratio and quercetin (2:1:1) presented encapsulation
efﬁciencies ranging from 62% to 81% [20].
On the other hand, no effect of SA on the entrapment efﬁciency of
RES in the phospholipid bilayer of liposomes was found. Furthermore,
the entrapment of QUE or RES did not squeeze out stearylamine
molecules from the phospholipid bilayer, since a positive surface
charge (zeta potential varying from 21 to 26 mV) of liposomes was
measured (Table 2). The liposomes prepared with SA containing
drug:HPβ-CD inclusion complexes showed the same zeta potential
than uncomplexed drugs, but the liposomes prepared without SA
showed smaller zeta potential values than those containing drug:
HPβ-CD inclusion complexes. Moreover, drug penetration into the
phospholipid bilayer can modify the zeta potential of liposomes. As
previously reported, neutral and positively charged liposomes were
more localized in the regional lymph nodes than negatively charged
liposomes after subcutaneous administration [29]. Based on these
ﬁndings, the liposomes prepared without SA (negatively charged
liposomes) were thus chosen for further experimental designs.
From the results, the co-encapsulation of QUE and Res in elastic
SDC-liposomes was considered using a full 23 experimental design.
In this study, the inﬂuence of liposome constituents and the incorpo-
ration of drugs into cyclodextrin inclusion complexes were evaluated.
All liposomal formulations presented a particle size greater than
100 nm (Table 3), being therefore suitable for subcutaneous adminis-
tration. The absorption of liposomes from the injection site after sub-
cutaneous administration is size-dependent and governed by the
transport of vesicles through the interstitial organized structure [25].
In fact, it was found that large liposomes (larger than 100 nm) will
have more difﬁculty in passing through the interstitial structure and
will remain at the site of injection. On the other hand, smaller vesicles
can migrate through the aqueous channels in the interstitial structure
and reach the lymphatic system.
No statistically signiﬁcant differences in the physicochemical pa-
rameters of elastic SDC- liposomes with QUE and RES entrapped or
encapsulated as cyclodextrin inclusion complexes were found. Simi-
lar results were obtained by Gillet et al. [9] for betametazone in
HPγCD and Crysmeb inclusion complexes encapsulated into elastic
SDC-liposomes. The encapsulation of drug inclusion complexes was
subsequently removed for further design experiments in order to ob-
tain more simple formulations with reduced costs.
The liposomal formulations run 9 and run 3 had optimal physico-
chemical parameters (Fig. 1), but differed in relation to CH concentra-
tions, which inﬂuence the rigidity of the phospholipid bilayer [30]
and, as a result, the stability of liposomes. In contrast, SDC providesa more ﬂuid bilayer as described by Chen et al. [31]. As the results
of the inﬂuence of CH and SDC concentrations on the physicochemical
parameters of liposomes were inconclusive, a full 23 experimental de-
sign was developed with the aim of encapsulating a large amount of
drug. Again, the mean size of all liposomal formulations was higher
than 100 nm (Table 4). The PDI of the selected liposomes formula-
tions varied between 0.2 and 0.3 (run 7), which is similar to liposomal
formulations with encapsulated ﬂavonoids obtained by Caddeo et al.
[5] with values of 0.237 and 0.270 and Mignet et al. [32]with values
of 0.320 and 0.350. Moreover, liposomes prepared with high SDC con-
centrations exhibited a smaller size than those with small SDC con-
centrations. This reduction of the particle size diameter of elastic
SDC-liposomes may be attributed to the increased ﬂexibility and re-
duced surface tension of these vesicles. In addition, the ﬁnal pH of
all formulations of elastic SDC-liposomes was 7.4. Indeed, it has
been reported the hydration of elastic SDC-liposomes prepared with
pH 7.4 buffer solutions reduces the vesicle size and improves drug
loading [31].
No signiﬁcant effect of CH concentrations on the physicochemical
parameters was found (Fig. 2). On the other hand, the increase in SDC
concentration caused a slight increase in the zeta potential (a statisti-
cally signiﬁcant positive effect), due to the presence of SDC molecules
negatively charged at the surface of liposomes.
The typical elastic SDC-liposomes obtained in this study were able
to entrap 23 times more quercetin and resveratrol (4620 μM) than
the formulations reported in the literature (100 μM). Yang et al. [2]
studied the combined effects of QUE and RES treatment (both at
100 μM) on 3T3-L1 cells and found a decrease in their viability
(73.5±0.9%) and an increase in apoptosis (310.3±9.6%), which
was more pronounced than the treatment with QUE or RES alone. In
addition, Park et al. [1] studied the effects of QUE and RES (100 μM)
associated with genistein (50 μM) on early- and mid-phase maturing,
and lipid-ﬁlled mature 3T3-L1 cells. A decrease in cell viability and an
induction of apoptosis were observed. Based on these ﬁndings, the as-
sociation of QUE and RES in liposomes is justiﬁed by the enhance-
ment of their synergistic effects.
In relation to SDC, the concentration used to dissolve localised fat
is 42 mg/ml, which has necrotic effects and causes various adverse
events [11]. In the present study the SDC concentration entrapped
in liposomes was 2.4 mg/ml, which is less than that used to dissolve
localised fat. However, a possible necrotic effect of the elastic liposo-
mal formulations produced cannot be ruled out.
Experimental designs showed that a reduction in the PC and
CH concentrations of 17.68% and 68.36%, respectively, can be
achieved when manufacturing liposomes containing three times
more nanoencapsulated SDC, QUE and RES (run 7). This formulation
presented a mean size and PDI values of 150 nm and 0.29, respec-
tively, a zeta potential slightly negative (−14 mV) and EE% higher
than 97%. One of the major problems limiting the widespread use of
liposomes is both physical and chemical stability [33]. Elastic lipo-
somes with entrapped QUE and RES were examined repeatedly over
time and compared with conventional liposomes; it was not observed
variations in the physicochemical properties after stability tests. Even
though their low zeta potential, the elastic liposomes (dispersion
form), no vesicle aggregation was observed during 45 days of storage
(Fig. 4) without variation of mean size and PDI. In addition, elastic
liposome had similar EE% values before and after lyophilisation
(> 95%). On this basis, the liposomes prepared with PC, CH and SDC
(69.65, 13.96 and 5.8 mM, respectively) containing QUE and RES at
4.62 mM were chosen for the in vitro release kinetics.
In vitro release kinetic studies have been used as a surrogate indi-
cator of in vivo drug availability [31], especially for poorly
water-insoluble drugs such as QUE and RES. In this study, the kinetics
showed an initial drug burst effect, which was considered important
for attaining higher levels of QUE and RES (>100 μM). The complete
release of drugs was attained at 60 h (Fig. 5). QUE and RES were
316 P.G. Cadena et al. / Biochimica et Biophysica Acta 1828 (2013) 309–316entrapped in the phospholipid bilayer of liposomes and the presence
of SDC probably enhanced lipid ﬂuidity thus permitting enhanced
drug leakage, as previously observed [34]. Our results corroborate
those of Chen et al. [31] for the faster kinetic proﬁle of fenoﬁbrate
from elastic (PC/SDC) than conventional (PC/CH) liposomes.
In spite of the satisfactory stability results of the SDC elastic QUE/
RES-loaded liposomes, their use in the injectable form need further
studies to ensure the safety and efﬁcacy of the treatment of subcuta-
neous fat reduction.
5. Conclusion
This study offered a new elastic SDC-liposomal formulation
containing co-encapsulated QUE and RES. The experimental design per-
mitted to the optimization of elastic QUE/RES-loaded liposomes with
suitable physicochemical properties and kinetic drug proﬁles for subcu-
taneous injection. This elastic SDC-liposome formulation thus displayed
promising features for upcoming experiments. Currently, in vitro and in
vivo studies are being undertaken in our laboratory to evaluate the po-
tential effectiveness of the liposomal formulation in dissolving localized
subcutaneous fat.
Abbreviations
AP Aqueous phase with HPβ-CD
CH Cholesterol
EE% Encapsulation efﬁciency
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